Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 166

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Identification of α-Enolase as an Autoantigen in Lung Cancer: Its Overexpression Is Associated with Clinical Outcomes

Chang, Gee-Chen, Liu, Ko-Jiunn, Hsieh, Chia-Ling, Hu, Tsai-Shu, Charoenfuprasert, Suparat, Liu, Hsiung-Kun, Luh, Kwen-Tay, Hsu, Li-Han, Wu, Chew-Wen, Ting, Chou-Chik, Chen, Chih-Yi, Chen, Kun-Chieh, Yang, Tsung-Ying, Chou, Teh-Ying, Wang, Wen-Hua, Whang-Peng, Jacqueline, Shih, Neng-Yao · 2006 · Clinical Cancer Research

Abstract

Purpose: Although existence of humoral immunity has been previously shown in malignant pleural effusions, only a limited number of immunogenic tumor-associated antigens (TAA) have been identified and associated with lung cancer. In this study, we intended to identify more TAAs in pleural effusion–derived tumor cells. Experimental Design: Using morphologically normal lung tissues as a control lysate in Western blotting analyses, 54 tumor samples were screened with autologous effusion antibodies. Biochemical purification and mass spectrometric identification of TAAs were done using established effusion tumor cell lines as antigen sources. We identified a p48 antigen as α-enolase (ENO1). Semiquantitative immunohistochemistry was used to evaluate expression status of ENO1 in the tissue samples of 80 patients with non–small cell lung cancer (NSCLC) and then correlated with clinical variables. Results: Using ENO1-specifc antiserum, up-regulation of ENO1 expression in effusion tumor cells from 11 of 17 patients was clearly observed compared with human normal lung primary epithelial and non-cancer-associated effusion cells. Immunohistochemical studies consistently showed high level of ENO1 expression in all the tumors we have examined thus far. Log-rank and Cox's analyses of ENO1 expression status revealed that its expression level in primary tumors was a key factor contributing to overall- and progression-free survivals of patients (P < 0.05). The same result was also obtained in the early stage of NSCLC patients, showing that tumors expressing relatively higher ENO1 level were tightly correlated with poorer survival outcomes. Conclusions: Our data strongly support a prognostic role of ENO1 in determining tumor malignancy of patients with NSCLC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-06-0324

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 166

Metadata

Authors
Chang, G.-C., Liu, K.-J., Hsieh, C.-L., Hu, T.-S., Charoenfuprasert, S., Liu, H.-K., Luh, K.-T., Hsu, L.-H., Wu, C.-W., Ting, C.-C., Chen, C.-Y., Chen, K.-C., Yang, T.-Y., Chou, T.-Y., Wang, W.-H., Whang-Peng, J., & Shih, N.-Y.
Venue
Clinical Cancer Research
Published
2006-10-01
Volume
12
Issue
19
Pages
5746-5754
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2111159494
Cited by
166
References
2
FWCI
3.10
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Identification of α-Enolase as an Autoantigen in Lung Cancer: Its Overexpression Is Associated with Clinical Outcomes. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-06-0324
The paper
Chang, G.-C., Liu, K.-J., Hsieh, C.-L., Hu, T.-S., Charoenfuprasert, S., Liu, H.-K., Luh, K.-T., Hsu, L.-H., Wu, C.-W., Ting, C.-C., Chen, C.-Y., Chen, K.-C., Yang, T.-Y., Chou, T.-Y., Wang, W.-H., Whang-Peng, J., & Shih, N.-Y. (2006). Identification of α-Enolase as an Autoantigen in Lung Cancer: Its Overexpression Is Associated with Clinical Outcomes. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-06-0324

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.